{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:07:34Z","timestamp":1792595254627,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.neo.2022.100857","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:51:09Z","timestamp":1671839469000},"page":"100857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era"],"prefix":"10.1016","volume":"36","author":[{"given":"Neevika","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-5137","authenticated-orcid":false,"given":"Kevin X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne A.","family":"Haas-Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-4760","authenticated-orcid":false,"given":"Pratiti","family":"Bandopadhayay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0001","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/1097-0142(197712)40:6<3123::AID-CNCR2820400656>3.0.CO;2-6","article-title":"Central nervous system tumors in children","volume":"40","author":"Farwell","year":"1977","journal-title":"Cancer"},{"issue":"12 Suppl 2","key":"10.1016\/j.neo.2022.100857_bib0002","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro. Oncol."},{"issue":"12 Suppl 2","key":"10.1016\/j.neo.2022.100857_bib0003","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"Suppl 10","key":"10.1016\/j.neo.2022.100857_bib0004","doi-asserted-by":"crossref","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","article-title":"Alex's lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16","author":"Ostrom","year":"2015","journal-title":"Neuro. Oncol."},{"issue":"12","key":"10.1016\/j.neo.2022.100857_bib0005","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JOP.2016.018622","article-title":"Treatment strategies for low-grade glioma in adults","volume":"12","author":"Oberheim Bush","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"7","key":"10.1016\/j.neo.2022.100857_bib0006","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr. Blood. Cancer"},{"issue":"8","key":"10.1016\/j.neo.2022.100857_bib0007","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.29907","article-title":"Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study","volume":"122","author":"Krishnatry","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.neo.2022.100857_bib0008","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jnci\/djp148","article-title":"Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study","volume":"101","author":"Armstrong","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0009","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group","volume":"68","author":"Wisoff","year":"2011","journal-title":"Neurosurgery"},{"issue":"22","key":"10.1016\/j.neo.2022.100857_bib0010","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO.2008.21.2738","article-title":"Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits","volume":"27","author":"Merchant","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.neo.2022.100857_bib0011","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1200\/JCO.2008.20.9494","article-title":"Phase II trial of conformal radiation therapy for pediatric low-grade glioma","volume":"27","author":"Merchant","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2022.100857_bib0012","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0013","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.neo.2022.100857_bib0014","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng.3500","article-title":"MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism","volume":"48","author":"Bandopadhayay","year":"2016","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.neo.2022.100857_bib0016","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.neo.2022.100857_bib0017","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/bpa.13060","article-title":"The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors","author":"Bale","year":"2022","journal-title":"Brain Pathol."},{"issue":"Pt 16","key":"10.1016\/j.neo.2022.100857_bib0018","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1242\/jcs.02470","article-title":"MAP kinase pathways","volume":"118","author":"Qi","year":"2005","journal-title":"J. Cell Sci."},{"issue":"21","key":"10.1016\/j.neo.2022.100857_bib0019","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1750-3639.2008.00225.x","article-title":"Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene","volume":"19","author":"Sievert","year":"2009","journal-title":"Brain Pathol."},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0021","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","article-title":"Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma","volume":"121","author":"Schindler","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0022","doi-asserted-by":"crossref","first-page":"e17948","DOI":"10.1371\/journal.pone.0017948","article-title":"BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications","volume":"6","author":"Dias-Santagata","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26838","article-title":"Neurofibromatosis type 1 and optic pathway glioma: molecular interplay and therapeutic insights","volume":"65","author":"Khatua","year":"2018","journal-title":"Pediatr. Blood. Cancer"},{"issue":"56","key":"10.1016\/j.neo.2022.100857_bib0024","doi-asserted-by":"crossref","first-page":"95516","DOI":"10.18632\/oncotarget.20764","article-title":"Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1\/TSC2 biallelic inactivation, and no BRAF mutations","volume":"8","author":"Bongaarts","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.neo.2022.100857_bib0025","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1","volume":"10","author":"Brems","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.neo.2022.100857_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13023-017-0588-2","article-title":"Non-optic glioma in adults and children with neurofibromatosis 1","volume":"12","author":"Sellmer","year":"2017","journal-title":"Orphanet. J. Rare. Dis."},{"issue":"2","key":"10.1016\/j.neo.2022.100857_bib0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0028","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00401-016-1549-x","article-title":"Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors","volume":"131","author":"Rivera","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0029","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-016-1639-9","article-title":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway","volume":"133","author":"Huse","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","article-title":"Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology","volume":"131","author":"Qaddoumi","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neo.2022.100857_bib0031","article-title":"Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics","author":"Yeo","year":"2022","journal-title":"Neuro. Oncol."},{"issue":"5","key":"10.1016\/j.neo.2022.100857_bib0032","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","article-title":"Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas","volume":"86","author":"Packer","year":"1997","journal-title":"J. Neurosurg."},{"issue":"4","key":"10.1016\/j.neo.2022.100857_bib0033","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/neuonc\/nos330","article-title":"A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method","volume":"15","author":"Walker","year":"2013","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.neo.2022.100857_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.884250","article-title":"Neurosurgery for optic pathway glioma: optimizing multidisciplinary management","volume":"9","author":"Samples","year":"2022","journal-title":"Front. Surg."},{"issue":"12","key":"10.1016\/j.neo.2022.100857_bib0035","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/cncr.29987","article-title":"Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children's Oncology Group","volume":"122","author":"Ater","year":"2016","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.neo.2022.100857_bib0036","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.neo.2022.100857_bib0037","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/neuonc\/nos202","article-title":"Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology","volume":"14","author":"Gnekow","year":"2012","journal-title":"Neuro. Oncol."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0038","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-2004-832355","volume":"216","author":"Gnekow","year":"2004","journal-title":"Klin. Padiatr."},{"issue":"24","key":"10.1016\/j.neo.2022.100857_bib0039","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2003.03.043","article-title":"Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy\u2013results of the first French prospective study for the French Society of Pediatric Oncology","volume":"21","author":"Laithier","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.neo.2022.100857_bib0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/neuonc\/2.4.213","article-title":"Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study","volume":"2","author":"Mahoney","year":"2000","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.neo.2022.100857_bib0041","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (<\/=16 years) low grade glioma - A final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"29","key":"10.1016\/j.neo.2022.100857_bib0042","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2022.100857_bib0043","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.2147\/OTT.S182721","article-title":"Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma","volume":"11","author":"Kakadia","year":"2018","journal-title":"Onco Targets Ther."},{"issue":"7","key":"10.1016\/j.neo.2022.100857_bib0044","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.neo.2022.100857_bib0045","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro. Oncol."},{"issue":"21","key":"10.1016\/j.neo.2022.100857_bib0046","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.neo.2022.100857_bib0047","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.neo.2022.100857_bib0048","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro. Oncol."},{"issue":"10","key":"10.1016\/j.neo.2022.100857_bib0049","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0050","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Sun","year":"2017","journal-title":"Neuro. Oncol."},{"issue":"5","key":"10.1016\/j.neo.2022.100857_bib0051","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ijrobp.2014.04.053","article-title":"Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas","volume":"89","author":"Greenberger","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.neo.2022.100857_bib0052","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.004","article-title":"Conformal radiation therapy for pediatric patients with low-grade glioma: results from the children's oncology group phase 2 study ACNS0221","volume":"103","author":"Cherlow","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.neo.2022.100857_bib0053","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-014-1696-7","article-title":"Prospective longitudinal evaluation of emotional and behavioral functioning in pediatric patients with low-grade glioma treated with conformal radiation therapy","volume":"122","author":"Willard","year":"2015","journal-title":"J. Neurooncol."},{"issue":"35","key":"10.1016\/j.neo.2022.100857_bib0054","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.19.01270","article-title":"Revisiting the role of radiation therapy for pediatric low-grade glioma","volume":"37","author":"Bitterman","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2022.100857_bib0055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro. Oncol."},{"issue":"Suppl 3","key":"10.1016\/j.neo.2022.100857_bib0056","doi-asserted-by":"crossref","first-page":"iii376","DOI":"10.1093\/neuonc\/noaa222.431","article-title":"LGG-53. PNOC001 (NCT01734512): a phase ii study of everolimus for recurrent or progressive pediatric low-grade gliomas (pLGG)","volume":"22","author":"Mueller","year":"2020","journal-title":"Neuro. Oncol."},{"issue":"Supplement_2","key":"10.1016\/j.neo.2022.100857_bib0057","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa215.186","article-title":"CTNI-19. phase I trial of day101 in pediatric patients with radiographically recurrent or progressive low-grade glioma (LGG)","volume":"22","author":"Wright","year":"2020","journal-title":"Neuro-oncol."},{"issue":"2","key":"10.1016\/j.neo.2022.100857_bib0058","doi-asserted-by":"crossref","first-page":"e28787","DOI":"10.1002\/pbc.28787","article-title":"A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma","volume":"68","author":"Wright","year":"2021","journal-title":"Pediatr. Blood. Cancer"},{"issue":"15","key":"10.1016\/j.neo.2022.100857_bib0059","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2022.100857_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis Type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","author":"Gross","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.neo.2022.100857_bib0061","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12885-016-2199-z","article-title":"Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression","volume":"16","author":"Woodfield","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.neo.2022.100857_bib0062","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.neo.2022.100857_bib0063","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11060-020-03592-8","article-title":"Trametinib for the treatment of recurrent\/progressive pediatric low-grade glioma","volume":"149","author":"Manoharan","year":"2020","journal-title":"J. Neurooncol."},{"issue":"11","key":"10.1016\/j.neo.2022.100857_bib0064","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/pbc.26086","article-title":"Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic\/chiasmatic glioma","volume":"63","author":"Lassaletta","year":"2016","journal-title":"Pediatr. Blood. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2022.100857_bib0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","article-title":"Response to trametinib treatment in progressive pediatric low-grade glioma patients","volume":"149","author":"Selt","year":"2020","journal-title":"J. Neurooncol."},{"issue":"24","key":"10.1016\/j.neo.2022.100857_bib0066","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1158\/1078-0432.CCR-17-3572","article-title":"A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory Braf V600 mutation-positive solid tumors","volume":"25","author":"Kieran","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.neo.2022.100857_bib0067","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"17_suppl","key":"10.1016\/j.neo.2022.100857_bib0068","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2002","article-title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab\u00a0+\u00a0tram) in BRAF V600\u2013mutant pediatric low-grade glioma (pLGG)","volume":"40","author":"Bouffet","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.neo.2022.100857_bib0069","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/MPH.0000000000001427","article-title":"Trametinib toxicities in patients with low-grade gliomas and diabetes insipidus: related findings?","volume":"42","author":"Egan","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"26","key":"10.1016\/j.neo.2022.100857_bib0070","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.neo.2022.100857_bib0071","doi-asserted-by":"crossref","first-page":"e28690","DOI":"10.1002\/pbc.28690","article-title":"Neuropsychological impact of trametinib in pediatric low-grade glioma: a case series","volume":"67","author":"Peterson","year":"2020","journal-title":"Pediatr. Blood. Cancer"},{"issue":"5","key":"10.1016\/j.neo.2022.100857_bib0072","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1212\/NXG.0000000000000616","article-title":"Impact of MEK inhibitor therapy on neurocognitive functioning in NF1","volume":"7","author":"Walsh","year":"2021","journal-title":"Neurol Genet"},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0073","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0074","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","article-title":"Response assessment in paediatric low-grade glioma: recommendations from the response assessment in pediatric neuro-oncology (RAPNO) working group","volume":"21","author":"Fangusaro","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.neo.2022.100857_bib0075","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro. Oncol."},{"issue":"49","key":"10.1016\/j.neo.2022.100857_bib0076","doi-asserted-by":"crossref","first-page":"84697","DOI":"10.18632\/oncotarget.20949","article-title":"Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K\/mTOR signaling pathways","volume":"8","author":"Jain","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.neo.2022.100857_bib0077","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"7","key":"10.1016\/j.neo.2022.100857_bib0078","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jnen\/nlx042","article-title":"Multiplex detection of pediatric low-grade glioma signature fusion transcripts and duplications using the nanostring ncounter system","volume":"76","author":"Ryall","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.neo.2022.100857_bib0079","first-page":"699","article-title":"Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy","volume":"19","author":"Kline","year":"2017","journal-title":"Neuro. Oncol."},{"issue":"7697","key":"10.1016\/j.neo.2022.100857_bib0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558622000823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558622000823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:13:48Z","timestamp":1761484428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558622000823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":80,"alternative-id":["S1476558622000823"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2022.100857","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2022.100857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100857"}}